IBIO

iBioB

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

At close

2026-06-11

View Chart

AI scenario view

RankAlpha Sentiment Codex

B+

Bull case

30%

Probability

Target price

$2.10

+23.5% vs current

Most likely

Base case

45%

Probability

Target price

$1.55

-8.8% vs current

B-

Bear case

25%

Probability

Target price

$1.10

-35.3% vs current

AI sentiment snapshot

Latest data as of 2026-05-04

AI commentary

Deterministic priors remain neutral to slightly soft, with mildly negative expected returns across 20- to 120-day horizons, modest evidence quality, and low catalyst density. Primary-source support is solid, but the setup is still mostly a filing-monitoring view centered on warrant expiry, first dosing, and runway rather than a broad fundamental re-rating case. Social context was not provided, and recent trusted-news coverage was absent in the packet, so confidence should stay restrained until the May 12, 2026 warrant expiry and the expected Q2 2026 first-dosing checkpoint are resolved.

RankAlpha Sentiment Codex - 2026-05-04

Open full AI memo

Evidence flagged

No evidence quality warning is currently attached to this memo.

Impact

standard

Confidence

AI events

2026-05-12catalystSeries G warrant expiry remains the nearest tradable overhangHigh impact

The April 8, 2026 8-K says the Series G warrants expire on May 12, 2026, 30 trading days after the company’s public announcement of Australian trial authorization, and that 27.945 million shares remained underlying those warrants as of the filing [#8-K-2026-04-08]. That leaves near-term dilution and trading overhang as the clearest short catalyst.

2026-06-30eventIBIO-600 first-patient dosing is the main operating milestoneHigh impact

The April 8, 2026 8-K says iBio received Clinical Trial Notification acknowledgement in Australia and ethics approval enabling initiation of the first-in-human IBIO-600 trial, with first participants expected to be dosed in the second quarter of 2026 [#8-K-2026-04-08]. Hitting that timeline would move the story from preclinical setup into human execution.

2027-02-10catalystRunway looks improved, but financing sensitivity is still part of the thesisHigh impact

The February 10, 2026 10-Q says iBio had about $28.7 million of cash and cash equivalents and about $24.0 million of investments in debt securities at December 31, 2025, and said its cash position plus the roughly $26 million private placement that closed on January 13, 2026 should fund operations for at least 12 months from filing; the same 10-Q also says the company’s history of losses, negative operating cash flow, and financing dependence had raised substantial doubt about continuing as a going concern [#10-Q-2026-02-10].

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-05-04 • Updated nightlySource: Internal modelMethodology